SARS-CoV-2

[npj Regenerative Medicine] Scientists evaluate the safety and efficacy outcomes of the most recent, placebo-controlled Phase I/II clinical studies that enrolled a larger number of patients, in order to provide a statistically relevant and comprehensive understanding of MSC’s therapeutic potential in severe COVID-19 patients.

[Scientific Reports] Molecular modeling methods were applied to build the inhibitory and non-inhibitory matrix metalloproteinase 9 (MMP-9)–TIMP-1 complexes, which allowed for a detailed description of these structures and allowed for a better understanding of the regulatory processes in which MMP-9 was involved.

[Scientific Reports] In lieu of tissue samples, investigators measured cytokines, inflammatory markers, viral RNA, microbiome composition, and antibody responses in stool samples from a cohort of 44 hospitalized COVID-19 patients.

[ACS Nano] SARS-CoV-2-naı̈ve individuals achieved levels similar to mild natural infection after the first vaccination; a second dose generated levels approaching severe natural infection.

[EMBO Journal] Investigating SARS-CoV-2 infection in tissue culture, researchers found that the protease TMPRSS2 determined the entry pathway used by the virus.

[Cell Reports] In a screen for new models of SARS-CoV-2 infection, researchers identified human H522 lung adenocarcinoma cells as naturally permissive to SARS-CoV-2 infection despite complete absence of ACE2 expression.